Paradigm Biopharmaceuticals Ltd. has released a press release.
Paradigm Receives $5.75m R&D Tax Incentive Refund
Earlier from Paradigm Biopharmaceuticals
- Drawdown of Tranche 4 under the Convertible Note Facility
- PAR Completes Enrolment in Pivotal Phase 3
- Results of Share Purchase Plan
- DSMB 20% Review Supports Phase 3, Moldova Activated